Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 2492 • ACR Convergence 2025
Autoantibody Profiles and Disease Trajectories in Early Systemic Sclerosis: Insights from a Prospective Cohort
Marzieh Jamali¹, Amisha Kaur¹, Suiyuan Huang¹, James St. Clair², John Varga¹, Carleigh Zahn², Erica Mulcaire-Jones¹, Alain Lescoat¹ and Dinesh Khanna¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Ann Arbor
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease with high mortality. Early stratification by autoantibody (SSc-Ab) profile may inform prognosis and management, but data…
Abstract Number: 1578 • ACR Convergence 2025
Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
Marc Scherlinger¹, Yannick dieudonne², Anna Molto³, Emmanuel Chatelus⁴, aurelien Guffroy⁵, Thierry Martin², Jacques-eric GOTTENBERG⁶, Celestine Simand⁷, Anne El Aatmani⁸, Justine Decroocq⁹, Eden Sebbag¹, Jean Sibilia¹⁰ and Jérôme AVOUAC¹¹, ¹Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, France, ²Immunology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, France, ³Assistance Publique Hôpitauxde Paris, Paris, France, ⁴Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ⁵CHU de Strasbourg, Strasbourg, ⁶Hautepierre Hospital, STRASBOURG, Alsace, France, ⁷ICANS, Strasbourg, France, ⁸CHU de Strasbourg, Strasbourg, France, ⁹APHP, Paris, France, ¹⁰Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, ¹¹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a severe autoimmune disease with limited treatments. While anti-CD19 CAR T-cell therapy shows promise, its use is limited by cost…
Abstract Number: 0705 • ACR Convergence 2025
Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
Ramona Govender¹, Elvis Hysa², Rosanna Campitiello³, Steven Wallaert¹, Matthias Vandycke¹, Emanuele Gotelli³, Tessa Du Four¹, Maurizio Cutolo⁴ and Vanessa Smith⁵, ¹University of Ghent, Ghent, Belgium, ²University of Genoa, Genoa, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵Ghent University Hospital, Gent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disorder. To date, no comparative multi-modal imaging data exist for precursor patients, those with Raynaud’s phenomenon (RP)…
Abstract Number: 2489 • ACR Convergence 2025
Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum
Kevin Chevalier¹, Benjamin Torreau², Marc Michel³, Bertrand Godeau³, Christian AGARD⁴, Thomas Papo⁵, Karim Sacré⁶, Brigitte Bader-Meunier⁷, Raphaele Seror⁸, Xavier Mariette⁹, Cacoub Patrice¹⁰, Ygal Benhamou¹¹, Hervé Levesque¹², Cécile goujard¹³, Olivier Lambotte¹⁴, Bernard Bonnotte¹⁵, Maxime Samson¹⁶, Félix Ackermann¹⁷, Jean Schmidt¹⁸, Pierre Duhaut¹⁸, Isabelle Kone-Paut¹⁴, Jean-Emmanuel Kahn¹⁹, Thomas Hanslik¹⁹, Nathalie Costedoat-Chalumeau²⁰, Benjamin Terrier²⁰, Alexis REGENT²¹, bertrand Dunogue²², Pascal Cohen²³, Véronique Le Guern²⁰, Eric HACHULLA²⁴, Benjamin Chaigne²² and Luc Mouthon²², ¹Université Paris Cité, Montrouge, France, ²Internal Medicine and Immunology, CHU Tours, Tours, France, ³Henri Mondor hospital, Créteil, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Bichat hospital, Paris, France, ⁶Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ⁷Necker hospital, Paris, France, ⁸Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ⁹Université Paris-Saclay, Le Kremlin Bicetre, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹¹Internal Medicine, CHU Rouen, Rouen, France, ¹²Rouen hospital, Rouen, France, ¹³Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹⁴Bicêtre hospital, Kremlin Bicêtre, France, ¹⁵Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Foch hospital, Suresnes, France, ¹⁸Amiens hospital, Amiens, France, ¹⁹Ambroise Paré hospital, Boulogne, France, ²⁰Cochin hospital, Paris, France, ²¹Hopital Cochin, Paris, France, ²²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Approximately 25% of MCTD patients will meet…
Abstract Number: 1579 • ACR Convergence 2025
Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Florian Käs⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Carina Mihai⁷, Muriel Elhai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc). Among radiomics features, the automated quantification of pulmonary vascular volume…
Abstract Number: 0699 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is one of the life threatening complications of systemic sclerosis (SSc). Up to 20-50% require long term dialysis and subsequently…
Abstract Number: 2488 • ACR Convergence 2025
Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
Kanako Chujo¹, Taichi Miyagi¹, Hiromi Shimada², Shusaku Nakashima², Yusuke Ushio¹, Koichi Sugihara², Mao Mizusaki², Naoto Manabe¹, Mayuko Wada², Risa Wakiya³ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Rituximab (RTX) was approved in Japan as a new treatment strategy for systemic sclerosis (SSc). Intravenous rituximab (375mg/m2) is administered once a week for…
Abstract Number: 1572 • ACR Convergence 2025
Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis
Gwenael Layec¹, Tracy Frech² and Anthony Donato³, ¹University of Nebraska, Omaha, NE, ²Vanderbilt University Medical Center, Nashville, TN, ³Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Muscle weakness and fatigue are frequent manifestations associated with systemic sclerosis (SSc). However, significant gaps remain in our understanding of the effects of SSc…
Abstract Number: 0698 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Systemic sclerosis (SSc) or scleroderma is a rare systemic autoimmune disease with multiple organ involvement. Renal involvement in SSc remains a significant concern, with…
Abstract Number: 2487 • ACR Convergence 2025
Cardiovascular and venous thromboembolic events in systemic sclerosis: Epidemiological analysis of the Clinical Practice Research Datalink
John Pauling¹, Rachel Charlton², Laura Ross³, Neil McHugh⁴ and Anita McGrogan², ¹North Bristol NHS Trust, Bristol, United Kingdom, ²University of Bath, Bath, ³St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia, ⁴University of Bath, Bath, United Kingdom
Background/Purpose: Cardiovascular disease is a leading cause of mortality in systemic sclerosis (SSc). We investigated the association between SSc and the occurrence of both cardiovascular…
Abstract Number: 1570 • ACR Convergence 2025
Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Francesco Bonomi¹, Ilaria Bisconti², Ilenia Mallia³, Greta Pellegrino⁴, Gabriele Ciuti⁵, Gloria Muolo², Martina Salerno², Simona Truglia², Cristiano Barbetta³, Silvia Peretti⁵, Serena Guiducci⁶, Valeria Riccieri⁷ and Silvia Bellando Randone³, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²Sapienza University of Rome, Rome, Rome, Italy, ³University of Florence, Florence, Italy, ⁴Rheumatology Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milano, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ⁵University Hospital Careggi, Florence, Italy, ⁶Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ⁷Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug that interferes with dendritic cells and monocytes, acidifies endosomes, and modulates toll-like receptors, reducing autoimmune responses and cell…
Abstract Number: 0690 • ACR Convergence 2025
Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease
Bo Broens¹, esther Nossent¹, Lilian Meijboom¹, Gerben Zwezerijnen¹, julia Spierings², Jeska de Vries-Bouwstra³, Jacob M. van Laar⁴, Conny van der Laken¹ and Alexandre Voskuijl⁵, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UMC Utrecht, Utrecht, Netherlands, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with early severe diffuse cutaneous systemic sclerosis (dcSSc) with interstitial lung disease (ILD) have poor prognosis. New tools are needed to improve treatment…
Abstract Number: 2479 • ACR Convergence 2025
REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.
Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Marco Di Paola¹, Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Andrea Claudio Ştețco⁷, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Systemic sclerosis (SS) is a rare connective tissue disorder characterized by progressive fibrosis of the skin and internal organs, including lungs, heart and kidneys.…
Abstract Number: 1565 • ACR Convergence 2025
Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
Zsuzsanna McMahan¹, Swapna Joshi², Jennifer Labus², Arissa Young², Andrea Low³, Vanessa Smith⁴, Susanna Proudman⁵, Antonia Valenzuela⁶, Phoebe Hunter⁷, Kristofer Andréasson⁸, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁹, ¹UT Health Houston, Houston, TX, ²UCLA, Los Angeles, ³Singapore General Hospital, SingHealth; Duke-NUS, Singapore, Singapore, ⁴Ghent University Hospital, Gent, Belgium, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ⁹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: GI disease is highly prevalent in systemic sclerosis (SSc) and adversely affects quality of life and survival in SSc. The pathogenesis of GI disease…
Abstract Number: 0689 • ACR Convergence 2025
Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
Blaz Burja¹, Paco Welsing², Alain Lescoat³, Andreas Eisenring⁴, Anna-Maria Hoffmann-Vold⁵, Claire Leroy David⁶, Dinesh Khanna⁷, Francesco Del Galdo⁸, Michele Iudici⁹, Janet Pope¹⁰, julia Spierings¹¹, Madelon Vonk¹², Marie-Elise Truchetet¹³, Martine Clergeau¹⁴, Michael Hughes¹⁵, Susan Murphy¹⁶, Tracy Frech¹⁷, Oliver Distler¹⁸ and Muriel Elhai¹⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³CHU Rennes - University Rennes, Rennes, France, ⁴Patient research partners, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶Patient research partners, Sos, France, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Leeds, Leeds, United Kingdom, ⁹Division of Rheumatology, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Geneva, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴Patient research partners, Paris, France, ¹⁵Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁶Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Michigan, ¹⁷Vanderbilt University Medical Center, Nashville, TN, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁹Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland
Background/Purpose: Inflammatory joint and/or tendon involvement affects up to 30% of patients with systemic sclerosis (SSc), resulting in pain, reduced joint function, and impaired patients'…

1
2
3
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].